About Vistagen Therapeutics (NASDAQ:VTGN)
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for depression and other central nervous system (CNS) disorders. The company's lead product candidate is AV-101, which is in Phase II development stage, an adjunctive treatment used for major depressive disorder. It also focuses on potential commercial applications of its human pluripotent stem cell (hPSC) technology platform to discover, rescue, develop, and commercialize new chemical entities (NCEs) for CNS and other diseases; and regenerative medicine involving hPSC-derived blood, cartilage, heart, and liver cells. In addition, the company develops CardioSafe 3D, an in vitro cardiac bioassay system for predicting human heart toxicity of small molecule NCEs. VistaGen Therapeutics, Inc. has licensing, sublicensing, and collaboration agreements with BlueRock Therapeutics, LP; U.S. National Institutes of Health; Cato Research Ltd.; and University Health Network. The company was founded in 1998 and is headquartered in South San Francisco, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:VTGN
CUSIPN/A
Phone650-577-3600
Debt
Debt-to-Equity RatioN/A
Current Ratio10.58%
Quick Ratio10.58%
Price-To-Earnings
Trailing P/E Ratio-0.58
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$1.25 million
Price / Sales15.94
Cash FlowN/A
Price / CashN/A
Book Value$0.07 per share
Price / Book12.43
Profitability
EPS (Most Recent Fiscal Year)($1.54)
Net Income$-10,250,000.00
Net MarginsN/A
Return on Equity-590.91%
Return on Assets-220.63%
Miscellaneous
Employees9
Outstanding Shares22,900,000
Vistagen Therapeutics (NASDAQ:VTGN) Frequently Asked Questions
What is Vistagen Therapeutics' stock symbol?
Vistagen Therapeutics trades on the NASDAQ under the ticker symbol "VTGN."
How were Vistagen Therapeutics' earnings last quarter?
What price target have analysts set for VTGN?
2 Wall Street analysts have issued 1 year target prices for Vistagen Therapeutics' shares. Their forecasts range from $4.00 to $22.00. On average, they anticipate Vistagen Therapeutics' stock price to reach $13.00 in the next year. View Analyst Ratings for Vistagen Therapeutics.
What are Wall Street analysts saying about Vistagen Therapeutics stock?
Here are some recent quotes from research analysts about Vistagen Therapeutics stock:
- 1. According to Zacks Investment Research, "VistaGen Therapeutics, Inc. is a biotechnology company. It is engaged in developing and commercializing product candidates for diseases and disorders involving the central nervous system. The company's lead product candidate consists of AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of major depressive disorder. VistaGen Therapeutics, Inc. is headquartered in South San Francisco, California. " (4/7/2018)
- 2. Maxim Group analysts commented, "Summary VistaGen announced the publication of a new study in The Journal of Pain demonstrating the effects of AV-101, its CNS candidate for depression, in four preclinical models of pain." (4/27/2017)
Who are some of Vistagen Therapeutics' key competitors?
Some companies that are related to Vistagen Therapeutics include Aileron Therapeutics (ALRN), Advaxis (ADXS), Eyenovia (EYEN), Gemphire Therapeutics (GEMP), Novelion Therapeutics (NVLN), Eleven Biotherapeutics (EBIO), GT Biopharma (GTBP), Novan (NOVN), OncoSec Medical (ONCS), Cardiome Pharma (CRME), MEI Pharma (MEIP), Northwest Biotherapeutics (NWBO), Alimera Sciences (ALIM), Pharmaxis (PXSLY) and Elite Pharmaceuticals (ELTP).
Who are Vistagen Therapeutics' key executives?
Vistagen Therapeutics' management team includes the folowing people:
- Mr. Shawn K. Singh J.D., CEO & Director (Age 55)
- Dr. H. Ralph Snodgrass Ph.D., Founder, Pres, Chief Scientific Officer & Director (Age 68)
- Mr. Jerrold D. Dotson CPA, CFO, VP & Sec. (Age 65)
- Dr. Mark A. Smith M.D., Ph.D., Chief Medical Officer (Age 63)
- Mr. Mark Adrian McPartland, VP of Corp. Devel. (Age 52)
Has Vistagen Therapeutics been receiving favorable news coverage?
Media coverage about VTGN stock has been trending somewhat positive this week, according to Accern. The research firm identifies positive and negative press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Vistagen Therapeutics earned a news impact score of 0.24 on Accern's scale. They also assigned news stories about the company an impact score of 46.05 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near term.
How do I buy shares of Vistagen Therapeutics?
Shares of VTGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Vistagen Therapeutics' stock price today?
One share of VTGN stock can currently be purchased for approximately $0.87.
How big of a company is Vistagen Therapeutics?
Vistagen Therapeutics has a market capitalization of $21.52 million and generates $1.25 million in revenue each year. The company earns $-10,250,000.00 in net income (profit) each year or ($1.54) on an earnings per share basis. Vistagen Therapeutics employs 9 workers across the globe.
How can I contact Vistagen Therapeutics?
Vistagen Therapeutics' mailing address is 343 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-577-3600 or via email at [email protected]
MarketBeat Community Rating for Vistagen Therapeutics (VTGN)
MarketBeat's community ratings are surveys of what our community members think about Vistagen Therapeutics and other stocks. Vote "Outperform" if you believe VTGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VTGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
Vistagen Therapeutics (NASDAQ:VTGN) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
2 Wall Street analysts have issued ratings and price targets for Vistagen Therapeutics in the last 12 months. Their average twelve-month price target is $13.00, suggesting that the stock has a possible upside of 1,394.25%. The high price target for VTGN is $22.00 and the low price target for VTGN is $4.00. There are currently 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $13.00 | $13.00 | $4.00 | $4.00 |
| Price Target Upside: | 1,394.25% upside | 983.33% upside | 104.08% upside | 104.08% upside |
Vistagen Therapeutics (NASDAQ:VTGN) Consensus Price Target History
Vistagen Therapeutics (NASDAQ:VTGN) Analyst Ratings History
Show:
(Data available from 4/24/2016 forward)
Vistagen Therapeutics (NASDAQ:VTGN) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Vistagen Therapeutics (NASDAQ VTGN) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 16.08%
Institutional Ownership Percentage: 20.85%
Vistagen Therapeutics (NASDAQ VTGN) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
(Data available from 1/1/2013 forward)
Vistagen Therapeutics (NASDAQ VTGN) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | This Morning's Technical Outlook on Biotech Stocks -- Vericel, Viking Therapeutics, VistaGen Therapeutics, and ZIOPHARM Oncology
www.bizjournals.com - April 24 at 8:20 AM |
 | Vistagen down 11% on mixed esketamine data
seekingalpha.com - April 20 at 5:21 PM |
 | VistaGen Therapeutics Receives European Patent regarding Methods of Production for AV-101
finance.yahoo.com - April 10 at 5:28 PM |
 | Vistagen Therapeutics (VTGN) Earns Buy Rating from Zacks Investment Research
www.americanbankingnews.com - April 7 at 1:43 PM |
| VistaGen Therapeutics initiates Phase 2 study of AV-101 for MDD
seekingalpha.com - April 5 at 10:12 AM |
| VistaGen Therapeutics Initiates Phase 2 Study of AV-101 for Major Depressive Disorder
finance.yahoo.com - April 5 at 10:12 AM |
| Vistagen Therapeutics (VTGN) Lifted to "Buy" at Zacks Investment Research
www.americanbankingnews.com - March 30 at 12:05 PM |
| VistaGen Therapeutics Receives a Notice of Allowance for Another Key U.S. Patent Covering Oral Formulations of AV-101
finance.yahoo.com - March 19 at 5:17 PM |
| VistaGen Therapeutics Receives Notice of Allowance for a Key U.S. Patent Covering Treatment of Depression with AV-101
finance.yahoo.com - March 7 at 6:33 PM |
| VistaGen Therapeutics to Present at Oppenheimer's 28th Annual Healthcare Conference on March 21, 2018
finance.yahoo.com - March 5 at 5:49 PM |
| VistaGen Therapeutics to Present at the Cowen and Company 38th Annual Health Care Conference on March 14, 2018
finance.yahoo.com - February 27 at 5:54 PM |
| VistaGen Therapeutics Reports Third Quarter Fiscal 2018 Financial Results
finance.yahoo.com - February 13 at 9:59 AM |
| Short Interest in Vistagen Therapeutics Inc (VTGN) Rises By 91.0%
www.americanbankingnews.com - February 11 at 1:08 AM |
| Chardan Capital Trims Vistagen Therapeutics (VTGN) Target Price to $22.00
www.americanbankingnews.com - February 8 at 12:56 PM |
| Vistagen Therapeutics (VTGN) Scheduled to Post Earnings on Monday
www.americanbankingnews.com - February 5 at 4:00 AM |
| VistaGen Therapeutics Issues Letter to Stockholders as Company Prepares to Initiate AV-101 Phase 2 Study for Major Depressive Disorder
finance.yahoo.com - January 30 at 9:31 AM |
| VistaGen Therapeutics to Provide Update on Phase 2 Study for Major Depressive Disorder and Outline Key 2018 Initiatives at the 14th Annual Noble Capital Markets' Investor Conference
finance.yahoo.com - January 24 at 8:07 AM |
 | VistaGen Therapeutics (VTGN) Receives FDA Fast Track Designation for AV-101 for the Treatment of MDD
www.streetinsider.com - January 4 at 10:22 AM |
| VistaGen Therapeutics Receives FDA Fast Track Designation for AV-101 for the Treatment of Major Depressive Disorder
finance.yahoo.com - January 3 at 9:41 AM |
| VistaGen Therapeutics to Present at the 10th Annual Biotech Showcase
finance.yahoo.com - December 18 at 10:50 AM |
| VistaGen Announces Closing of $15,000,000 Underwritten Offering of Common Stock and Warrants to Purchase Common Stock
finance.yahoo.com - December 13 at 4:40 PM |
| Stocks- Wall Street Set for Higher Opening as Bitcoin Futures Surge
finance.yahoo.com - December 11 at 11:08 AM |
| VistaGen Therapeutics Expands Stem Cell Patent Portfolio with New U.S. Patent on Methods for Producing Blood Cells, Platelets and Bone Marrow Stem Cells with Potential to Treat Autoimmune Disorders and Cancer
finance.yahoo.com - December 8 at 10:27 AM |
| VistaGen Soars on Patent Announcement, Pipeline Review, and Analysts Opinion
finance.yahoo.com - December 7 at 10:50 AM |
| Vistagen Therapeutics Inc (VTGN) Wows Investors with a New Patent Victory
finance.yahoo.com - December 6 at 4:31 PM |
| VistaGen Therapeutics Granted U.S. Patent regarding Methods of Production for AV-101
finance.yahoo.com - December 6 at 10:42 AM |
| VistaGen Therapeutics Reports Second Fiscal Quarter 2018 Financial Results and Provides Business Update
finance.yahoo.com - November 12 at 1:17 PM |
| VistaGen Therapeutics, Inc. (VTGN) Announces Quarterly Earnings Results
www.americanbankingnews.com - November 10 at 5:36 PM |
| VistaGen Therapeutics Receives European Patent for AV-101 for Treatment of Depression
finance.yahoo.com - November 6 at 9:05 AM |
| VistaGen Therapeutics, Inc. (VTGN) Scheduled to Post Quarterly Earnings on Monday
www.americanbankingnews.com - November 6 at 6:26 AM |
| Is VistaGen Therapeutics Inc’s (VTGN) Balance Sheet A Threat To Its Future?
finance.yahoo.com - November 4 at 6:19 AM |
| VistaGen Announces FDA Authorization to Initiate Phase 2 Study of AV-101 for Major Depressive Disorder
finance.yahoo.com - October 28 at 8:34 AM |
| Should You Worry About VistaGen Therapeutics Inc (VTGN) Cash Runway?
finance.yahoo.com - October 6 at 12:41 PM |
| VistaGen Therapeutics (VTGN) Receives Notice of Allowance for U.S. Patent Regarding Methods of Production for AV-101
www.streetinsider.com - September 30 at 12:50 AM |
| VistaGen Therapeutics (VTGN) Receives Notice of Allowance for US Patent Regarding Methods of Production for AV-101 - StreetInsider.com
www.streetinsider.com - September 29 at 2:48 PM |
| VistaGen Announces Closing of Underwritten Offering of Common Stock and Warrants to Purchase Common Stock
finance.yahoo.com - September 7 at 11:06 AM |
| VistaGen Announces Pricing of Underwritten Offering of Common Stock and Warrants to Purchase Common Stock
finance.yahoo.com - September 1 at 11:00 AM |
| VistaGen Therapeutics Expands VistaStem's Scientific Advisory Board with Appointment of Medicinal Chemistry Expert, David Rotella, PhD
finance.yahoo.com - August 22 at 7:44 AM |
| VistaGen Therapeutics, Inc. (VTGN) Releases Quarterly Earnings Results
www.americanbankingnews.com - August 15 at 10:46 AM |
| VistaGen Receives Notice of Allowance from U.S. Patent and Trademark Office for U.S. Patent regarding Breakthrough Methods for Producing Blood Cells, Platelets and Bone Marrow Stem Cells with Potential to Treat Autoimmune Disorders and Cancer
finance.yahoo.com - August 9 at 8:58 AM |
| VistaGen Therapeutics Appoints Dr. Mark Wallace to Clinical Advisory Board to Advance AV-101 as a Potential Non-Opioid Treatment for Neuropathic Pain
finance.yahoo.com - July 11 at 9:22 AM |
 | VistaGen Therapeutics Receives European Patent Office Notice of Intention to Grant European Patent for AV-101
us.rd.yahoo.com - March 29 at 10:09 AM |
| 9:02 am VistaGen: EPO has issued a Notice of Intention to Grant the co's European Patent Application for AV-101
us.rd.yahoo.com - March 29 at 10:09 AM |
| Coverage initiated on VistaGen by Maxim Group
us.rd.yahoo.com - March 28 at 10:56 PM |
 | VistaGen Therapeutics Inc. (US: VTGN) to Ring The Nasdaq Stock Market Closing Bell
www.marketwatch.com - March 11 at 10:54 AM |
| VISTAGEN THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events
biz.yahoo.com - December 15 at 7:13 AM |
| VISTAGEN THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition
biz.yahoo.com - November 14 at 8:33 PM |
| VISTAGEN THERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
biz.yahoo.com - September 27 at 7:56 PM |
| VISTAGEN THERAPEUTICS, INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Fina
biz.yahoo.com - August 17 at 8:31 PM |
| VISTAGEN THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and E
biz.yahoo.com - June 22 at 6:04 AM |
Vistagen Therapeutics (NASDAQ:VTGN) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Vistagen Therapeutics (NASDAQ:VTGN) Income Statement, Balance Sheet and Cash Flow Statement
Vistagen Therapeutics (NASDAQ VTGN) Stock Chart for Tuesday, April, 24, 2018
Loading chart…
